Biologics Development and Manufacturing: Solving Challenges Through Engineering
This lecture will focus on the development and engineering of biological drugs, with a particular emphasis on our research into the combination of affinity proteins and viral vectors for more precise targeting.
Time: Tue 2026-02-10 10.00 - 11.00
Location: FA32 Albanova
Language: Swedish
Participating: Magdalena Malm, Protein Technology
Biological drugs, including various affinity proteins and gene therapies based on viral vectors, enable specific treatment of many different diseases.
Protein engineering enables the development of more advanced biological drugs with tailored properties, such as improved targeting or mechanism of action. However, more advanced biological drugs may require more customised and tailored cell factories for their production in order not to limit the clinical development or availability of these drugs.
Engineering both biological drugs and their cell factories for production may be the key to avoiding the need for excessively large volumes of cell factory cultures to produce sufficient biological material to meet clinical needs.
The lecture will also describe how we have mapped and improved two of the most commonly used mammalian cell factories, CHO and HEK293, for the production of biological drugs.